## FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
Section 16 Form 4 or Form 5		

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL					
OMB Number: 3235-0287					
Estimated average burden					
hours per response.	0.5				

1. Name and Address of Reporting Person <sup>*</sup> Agrawal Amit (Last) (First) (Middle) C/O BELLEROPHON THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 301		(Middle) RAPEUTICS, INC.	2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [ BLPH ] - 3. Date of Earliest Transaction (Month/Day/Year) 07/08/2015	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Operating Officer			
(Street) HAMPTON (City)	NJ (State)	08827 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 8. Price of Derivative Security 1. Title of 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 9. Number of 10. 11. Nature 2 Ownership Form: Derivative Execution Date, if any Conversion Transaction Code (Instr. of Securities Underlying Derivative Expiration Date derivative of Indirect Date (Month/Day/Year) (Month/Day/Year) Beneficial or Exercise Securities Securities Price of Derivative 8) Acquired (A) or Disposed Derivative Sec (Instr. 3 and 4) Beneficially Owned Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) Security (Instr. 5) Direct (D) or Indirect Security of (D) (Instr. 3, 4 and 5) Following (I) (Instr. 4) Reported Transaction(s) Amount (Instr. 4) Number Expiration Date Code v (A) (D) Exercisable Date Title of Shares Stock Option Commor \$8.23 07/08/2015 А 100,000 (1) 07/07/2025 100,000 \$<mark>0</mark> 100,000 D (right to Stock

Explanation of Responses:

buy)

1. This option was granted on July 8, 2015. This option vests in five equal annual installments, with the first installment vesting on the date of grant and the remaining four installments vesting annually on each of the first four anniversaries of the date of grant.

## /s/ Amit Agrawal

\*\* Signature of Reporting Person

07/10/2015

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.